Acrux completes Phase I trial of testosterone lotion
Wednesday, 06 October, 2004
Acrux (ASX: ACR) has completed a Phase I clinical trial of its testosterone metered-dose lotion for the treatment of hypogonadism, or low testosterone, in men.
The proof-of-concept study compared Acrux's product with the current market leader, a commercially available testosterone gel in five men with low testosterone. The trial was performed at Prince Henry's Institute of Medical Research in Melbourne, and was sponsored by Acrux subsidiary Acrux DDS.
The company will now seek advice on the appropriate regulatory path for approval in major world markets including the US, CEO Igor Gonda said.
Preventing neural graft rejection in Parkinson's patients
Researchers have engineered a way to fool the immune system into accepting neural grafts as part...
Retinal health linked to dementia risk, study shows
Researchers have discovered that the blood vessels at the back of the eye — called retinal...
Pancreatic cancer hijacks metabolism switch to help it spread
Pancreatic cancer hijacks a molecule known for regulating physiological processes, such as food...
